Invivyd (IVVD) Research & Development (2021 - 2026)
Invivyd (IVVD) reported Research & Development of $29.37 million for Q2 2026, up 206.8% from $9.57 million a year earlier.
Powered by 
Analysis
Invivyd (IVVD) Research & Development (2021 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Invivyd's Research & Development came in at $57.03 million, down 40.6% year-over-year; for FY2025, it came in at $38.31 million, down 72.1% from FY2024.
- Research & Development has declined for four consecutive years, though with a five-year compound annual growth rate of 11.7% (FY2020 to FY2025).
- By year, Research & Development came in at $137.25 million in FY2024 (-13.5%), $158.66 million in FY2023 (-11.5%), $179.21 million in FY2022 (-2.0%) and $182.89 million in FY2021 (+731.6%).
- The Q2 2026 figure ranks as the highest quarterly Research & Development since Q3 2024.
- Year over year, Research & Development gained in two of the last seven quarters, with an average decline of 0.4%.
- The high point for year-over-year Research & Development in five years was Q4 2023 (growth of 212.6%); the low point was Q3 2025 (a decline of 86.1%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Invivyd | 280.02 Mn | -226.62 Mn | 13.01 Mn | 29.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.37 Mn |
| Dec 31, 2025 | 10.05 Mn |
| Sep 30, 2025 | 8.05 Mn |
| Jun 30, 2025 | 9.57 Mn |
| Mar 31, 2025 | 10.64 Mn |
| Dec 31, 2024 | 17.91 Mn |
| Sep 30, 2024 | 57.85 Mn |
| Jun 30, 2024 | 30.33 Mn |
| Mar 31, 2024 | 31.16 Mn |
| Dec 31, 2023 | 62.27 Mn |
| Sep 30, 2023 | 25.57 Mn |
| Jun 30, 2023 | 43.62 Mn |
| Mar 31, 2023 | 27.20 Mn |
| Dec 31, 2022 | 19.92 Mn |
| Sep 30, 2022 | 30.13 Mn |
| Jun 30, 2022 | 37.13 Mn |
| Mar 31, 2022 | 92.04 Mn |
| Dec 31, 2021 | 68.43 Mn |
| Sep 30, 2021 | 45.37 Mn |
| Jun 30, 2021 | 35.07 Mn |
API Access
Invivyd Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=IVVD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "IVVD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=IVVD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();